Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
From the Program of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA; the Program of Clinical Statistics, Fred Hutchinson Cancer Research Center, Seattle, WA; the Department of Medicine, University of Washington, Seattle; and the Department of Laboratory Medicine, University of Washington, Seattle.w'(x/1, 百拇医药
Prophylactic fluconazole prevents candidiasis; however, this drug has no activity against molds. We performed a randomized trial to determine whether prophylactic itraconazole prevents invasive mold infections (IMIs). A total of 304 patients receiving allogeneic stem cell transplants (SCT) were randomized to receive fluconazole (400 mg/d) or itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily) for 180 days after SC transplantation, or until 4 weeks after discontinuation of graft-versus-host disease (GVHD) therapy. Proven or probable invasive fungal infections (IFI) were evaluated by intent-to-treat and "on-treatment" analyses. More patients in the itraconazole arm developed hepatotoxicities, and more patients were discontinued from itraconazole because of toxicities or gastrointestinal (GI) intolerance (36% versus 16%, P < .001). Intent-to-treat analysis demonstrated no difference in the incidence of IFI during the intended study period (fluconazole 16% versus itraconazole 13%, P = .46); however, fewer patients in the itraconazole arm developed IFI on treatment (fluconazole 15% versus itraconazole 7%, P = .03). Itraconazole provided better protection against IMI (fluconazole 12% versus itraconazole 5%, P = .03), but similar protection against candidiasis (3% versus 2%, P = .69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy.
This article has been cited by other articles:a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
"Home page"a&7m, 百拇医药
""a&7m, 百拇医药
BMJ "Home page"a&7m, 百拇医药
Minervaa&7m, 百拇医药
BMJ, March 6, 2004; 328(7439): 592 - 592.a&7m, 百拇医药
[Full Text] [PDF]a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
"Home page"a&7m, 百拇医药
""a&7m, 百拇医药
Blood "Home page"a&7m, 百拇医药
K. A. Marr, W. Leisenring, F. Crippa, J. T. Slattery, L. Corey, M. Boeckh, and G. B. McDonalda&7m, 百拇医药
Cyclophosphamide metabolism is affected by azole antifungalsa&7m, 百拇医药
Blood, February 15, 2004; 103(4): 1557 - 1559.a&7m, 百拇医药
[Abstract] [Full Text] [PDF]a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
Related Articles in Blood Online :a&7m, 百拇医药
Fungal infection in hemato-oncologic patients: better to prevent than to treat?.a&7m, 百拇医药
Jan W. van't Wout and Jaap T. van Dissel Blood 2004 103: 1182-1183. [Full Text](Kieren A. Marr Fulvio Crippa Wendy Leisenring Maggie Hoyle Michael Boeckh S. Arunmozhi Balajee W. Ga)
Prophylactic fluconazole prevents candidiasis; however, this drug has no activity against molds. We performed a randomized trial to determine whether prophylactic itraconazole prevents invasive mold infections (IMIs). A total of 304 patients receiving allogeneic stem cell transplants (SCT) were randomized to receive fluconazole (400 mg/d) or itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily) for 180 days after SC transplantation, or until 4 weeks after discontinuation of graft-versus-host disease (GVHD) therapy. Proven or probable invasive fungal infections (IFI) were evaluated by intent-to-treat and "on-treatment" analyses. More patients in the itraconazole arm developed hepatotoxicities, and more patients were discontinued from itraconazole because of toxicities or gastrointestinal (GI) intolerance (36% versus 16%, P < .001). Intent-to-treat analysis demonstrated no difference in the incidence of IFI during the intended study period (fluconazole 16% versus itraconazole 13%, P = .46); however, fewer patients in the itraconazole arm developed IFI on treatment (fluconazole 15% versus itraconazole 7%, P = .03). Itraconazole provided better protection against IMI (fluconazole 12% versus itraconazole 5%, P = .03), but similar protection against candidiasis (3% versus 2%, P = .69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy.
This article has been cited by other articles:a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
"Home page"a&7m, 百拇医药
""a&7m, 百拇医药
BMJ "Home page"a&7m, 百拇医药
Minervaa&7m, 百拇医药
BMJ, March 6, 2004; 328(7439): 592 - 592.a&7m, 百拇医药
[Full Text] [PDF]a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
"Home page"a&7m, 百拇医药
""a&7m, 百拇医药
Blood "Home page"a&7m, 百拇医药
K. A. Marr, W. Leisenring, F. Crippa, J. T. Slattery, L. Corey, M. Boeckh, and G. B. McDonalda&7m, 百拇医药
Cyclophosphamide metabolism is affected by azole antifungalsa&7m, 百拇医药
Blood, February 15, 2004; 103(4): 1557 - 1559.a&7m, 百拇医药
[Abstract] [Full Text] [PDF]a&7m, 百拇医药
""a&7m, 百拇医药
""a&7m, 百拇医药
Related Articles in Blood Online :a&7m, 百拇医药
Fungal infection in hemato-oncologic patients: better to prevent than to treat?.a&7m, 百拇医药
Jan W. van't Wout and Jaap T. van Dissel Blood 2004 103: 1182-1183. [Full Text](Kieren A. Marr Fulvio Crippa Wendy Leisenring Maggie Hoyle Michael Boeckh S. Arunmozhi Balajee W. Ga)